Eurofins is a trusted outsourcing partner for many in the pharma industry, and we are pleased that they have added the Erenna system to their Bioanalytical Lab Services offering
St Charles, MO (PRWEB) April 02, 2015
Eurofins Bioanalytical Services, a leading provider of bioanalytical testing to the biopharmaceutical industry, today announced introduction of services on the Singulex Erenna Immunoassay platform. The system is the latest high-tech addition to the laboratory that focuses on the Bioanalysis of large molecule therapeutics.
Biopharmaceutical companies face ever more demanding technical challenges in their quest to develop safer, better drugs. The Singulex Erenna immunoassay system can detect proteins at the femtogram / mL level, enabling the measurement of ultra-low levels of protein. The platform is used in pharmacokinetic studies, to measure biomarkers, and evaluate the immune response to administered large molecule therapeutics - especially where detection levels are a challenge.
“The Erenna immunoassay system, powered by Singulex’s SMC™ technology, provides unprecedented quantification of protein targets at low and high abundance, providing a complete data set for a sponsor to make informed decisions and accelerate program success,” said Dr. Paul Wheeler, Vice President of Life Science Sales and Marketing at Singulex. “Eurofins is a trusted outsourcing partner for many in the pharma industry, and we are pleased that they have added the Erenna system to their Bioanalytical Lab Services offering.”
Eurofins Bioanalytical Serrvices has already partnered with several of our clients to develop and transfer novel methods on the Erenna system. ” said Dr Jim Hulse, General Manager of Eurofins Bioanalytical Services, “ we look forward to working with additional users of the platform as we begin offering services using the existing biomarker assay kits available from Singulex”
More information at http://www.eurofins.com/bioanalyticalservices